Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Will the drugs still work? Transmission of resistant HIV

The clinical impact of HIV in developed countries has been markedly reduced through the use of combination antiretroviral drug therapy. But strains of HIV resistant to some or all of these drugs have evolved and are spreading. How fast will they grow? (pages 1016–1020)

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Blower, S. et al. Predicting the unpredictable: The transmission of drug-resistant HIV. Nature Med. 7, 1016–1020 (2001).

    Article  CAS  Google Scholar 

  2. Hecht, F.M. et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N. Engl. J. Med. 339, 307–311 (1998).

    Article  CAS  Google Scholar 

  3. Yerly, S. et al. Transmission of antiretroviral drug resistant HIV1 variants. Lancet 354, 729–733 (1999).

    Article  CAS  Google Scholar 

  4. UK Collaborative Group on Monitoring the transmission of HIV drug resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the UK. Brit. Med. J. 322, 1087–1088 (2001).

  5. Little, S.J. et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. 8th Conference on Retroviruses and Opportunistic Infections, Chicago (4–8 February 2001).

  6. Leigh Brown, A.J. et al. Transmission fitness of drug-resistant virus and the prevalence of resistance in the treated population. Abstract 145. Antivir. Ther. 6, 112 (2001).

    Google Scholar 

  7. Miller, V. et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14, 2857–2867 (2000).

    Article  CAS  Google Scholar 

  8. Argentina NTTC on behalf of the Esprit International Team. Preliminary results of Esprit: Predictors of dosage reduction or cycle interruption during the first three cycles of IL-2. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires (8–11 July 2001).

  9. Youle, M. et al. Randomised study of intermittent subcutaneous interleukin-2 (IL-2) therapy: Without antiretovirals versus no treatment. Abstract LBOr028. 13th International Conference on AIDS, Durban (July 2000).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Phillips, A. Will the drugs still work? Transmission of resistant HIV. Nat Med 7, 993–994 (2001). https://doi.org/10.1038/nm0901-993

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0901-993

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing